logo

SPRC

SciSparc
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 2
Price Hits New Low
Price Hits 52-week low

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About SPRC

Scisparc Ltd.

A company that develops Cannabinoid technologies in treatment of central nervous system disorders

Pharmaceutical
08/23/2004
12/22/2021
NASDAQ Stock Exchange
2
12-31
Common stock
20 Raul Wallenberg St., Tower A, 2nd Floor, Tel Aviv 6971916, Israel
--
SciSparc Ltd., a pharmaceutical company, was incorporated and started operations in Israel on August 23, 2004. The company is a clinical professional pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. Based on this, the company is currently working on the following development projects based on Δ 9-tetrahydrocannabinol (THC) and non-psychoactive cannabinol (CBD): THX-110 for the treatment of Tourette's syndrome (TS) and obstructive sleep apnea; THX-160 for the treatment of chronic and acute pain; and THX-210 for the treatment of chronic and acute pain, autism spectrum disorder and epilepsy.

Company Financials

EPS

SPRC has released its 2016 Q4 earnings. EPS was reported at -0.80, versus the expected 0.00, missing expectations. The chart below visualizes how SPRC has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime